CA3227139A1 - Methods for inhibiting the progression of oxidative retinal diseases - Google Patents

Methods for inhibiting the progression of oxidative retinal diseases Download PDF

Info

Publication number
CA3227139A1
CA3227139A1 CA3227139A CA3227139A CA3227139A1 CA 3227139 A1 CA3227139 A1 CA 3227139A1 CA 3227139 A CA3227139 A CA 3227139A CA 3227139 A CA3227139 A CA 3227139A CA 3227139 A1 CA3227139 A1 CA 3227139A1
Authority
CA
Canada
Prior art keywords
day
patient
progression
ester
rate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3227139A
Other languages
English (en)
French (fr)
Inventor
Karsten Schmidt
Mikhail Shchepinov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biojiva LLC
Original Assignee
Biojiva LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biojiva LLC filed Critical Biojiva LLC
Priority to CA3311344A priority Critical patent/CA3311344A1/en
Publication of CA3227139A1 publication Critical patent/CA3227139A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3227139A 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases Pending CA3227139A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3311344A CA3311344A1 (en) 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163224679P 2021-07-22 2021-07-22
US202163224690P 2021-07-22 2021-07-22
US202163224674P 2021-07-22 2021-07-22
US63/224,690 2021-07-22
US63/224,674 2021-07-22
US63/224,679 2021-07-22
PCT/US2022/038072 WO2023004151A1 (en) 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3311344A Division CA3311344A1 (en) 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases

Publications (1)

Publication Number Publication Date
CA3227139A1 true CA3227139A1 (en) 2023-01-26

Family

ID=84979648

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3227139A Pending CA3227139A1 (en) 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases
CA3311344A Pending CA3311344A1 (en) 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3311344A Pending CA3311344A1 (en) 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases

Country Status (8)

Country Link
US (1) US20250099415A1 (cg-RX-API-DMAC7.html)
EP (1) EP4373479A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526939A (cg-RX-API-DMAC7.html)
KR (1) KR20240036651A (cg-RX-API-DMAC7.html)
AU (1) AU2022313207A1 (cg-RX-API-DMAC7.html)
CA (2) CA3227139A1 (cg-RX-API-DMAC7.html)
IL (1) IL310210A (cg-RX-API-DMAC7.html)
WO (1) WO2023004151A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240091187A1 (en) * 2022-09-02 2024-03-21 Biojiva Llc Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270739A1 (en) * 2005-04-28 2006-11-30 Trustees Of Tufts College Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation
US20100303887A1 (en) * 2007-07-30 2010-12-02 Bazan Nicolas G DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells
EP2219638A2 (en) * 2007-10-29 2010-08-25 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Lipoxin a4 protection for retinal cells
US10058522B2 (en) * 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
WO2017091279A1 (en) * 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
WO2020102596A1 (en) * 2018-11-15 2020-05-22 Retrotope, Inc. Deuterated compounds, compositions, and uses

Also Published As

Publication number Publication date
KR20240036651A (ko) 2024-03-20
IL310210A (en) 2024-03-01
CA3311344A1 (en) 2026-06-21
AU2022313207A1 (en) 2024-02-29
US20250099415A1 (en) 2025-03-27
WO2023004151A1 (en) 2023-01-26
JP2024526939A (ja) 2024-07-19
EP4373479A1 (en) 2024-05-29
EP4373479A4 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
EP3735963B1 (en) Self-emulsifying composition of omega-3 fatty acid
US6417233B1 (en) Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiguinones and methods of using same
EP3023099B1 (en) Self-emulsifying composition of -3 fatty acid
US5834032A (en) Compositions and methods for treating diabetes
EP3248599A1 (en) Omega-3 fatty acid self-emulsifying composition
UA76108C2 (en) Use of therapeutic combination of fatty acids
US11351143B1 (en) Methods of treating amyotrophic lateral sclerosis
WO2003072111A2 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
EP1689413A2 (en) Glycerophospholipids containing omega-3 and omega-6 fatty acids
CA3210773A1 (en) Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof
EP3986418A1 (en) Parenteral lysophosphatidylcholine formulations such as lpc-dha, lpc-epa and their use in therapy
US20220249422A1 (en) Methods of treating amyotrophic lateral sclerosis
AU2006324155A1 (en) Intravenous essential fatty acid emulsion
WO2023004151A1 (en) Methods for inhibiting the progression of oxidative retinal diseases
KR20180010181A (ko) Apo c3 의 저하를 위한 티아 옥소 화합물의 용도
CN118019529A (zh) 抑制氧化性视网膜疾病进展的方法
US20240091187A1 (en) Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof
JP2025507361A (ja) 網膜酸化的疾患の治療に対する患者の反応をモニタリングする方法
JPS6011422A (ja) 抗筋ジストロフイ−症剤
KR20260010331A (ko) L-세린의 리포좀 제형 및 이의 제조 방법
JP2025506208A (ja) Als治療のための相乗的併用療法
JPH05139966A (ja) 月経困難症予防または治療剤と月経困難症予防機能性食品
JPS6011421A (ja) 血中脂質降下剤
EA046793B1 (ru) Применение композиции (варианты) для профилактического или терапевтического лечения кальцификации сосудов
JPS6256133B2 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260109

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260309

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260511

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260708